Login
$TYRA
$19.74 -$0.29 (1.42%) Live

$TYRA 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients

15 Sep 2026 8-K: Other Events

Tyra Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement with Jefferies LLC, Guggenheim Securities, LLC, Cantor Fitzgerald & Co., Barclays Capital Inc. and each of the other Underwriters named in Schedule A ...

09 Sep 2026 8-K: Other Events

On September 9, 2026, Tyra Biosciences, Inc. (TYRA or the Company) announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with Fibroblast Growth Factor Receptor (FGFR) 3-altered low-grade inter...

04 Aug 2026 8-K: Results of Operations and Financial Condition

- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) -

02 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Tyra Biosciences, Inc. (the Company) held its 2026 Annual Meeting of Stockholders (the 2026 Annual Meeting) on May 28, 2026. The following is a brief description of each matter voted upon at the 2026 Annual Meeting and the number of vote...

13 May 2026 8-K: Results of Operations and Financial Condition

- Advanced “dabogratinib 3x3” strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH -

17 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

02 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company’s principal accounting officer, succeeding Alan Fuhrman, the Company’s Chief F...

04 Mar 2026 8-K: Other Events

On March 4, 2026, Tyra Biosciences, Inc. (the “Company”) agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. The Company expects to receive $126.0 milli...

02 Mar 2026 8-K: Results of Operations and Financial Condition

- Launched “dabogratinib 3x3” strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -

01 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

05 Nov 2025 8-K: Results of Operations and Financial Condition

- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 -

22 Aug 2025 8-K: Other Events

On August 21, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first child has been dosed in the BEACH301 Phase 2 clinical study of dabogratinib (formerly TYRA-300) in children with achondroplasia. The Company expects to ...

14 Aug 2025 8-K: Results of Operations and Financial Condition

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) -

30 Jun 2025 8-K: Other Events

On June 30, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first patient has been dosed in the SURF302 Phase 2 clinical study of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer (IR NMIBC).

29 May 2025 8-K: Submission of Matters to a Vote of Security Holders

Tyra Biosciences, Inc. (the Company) held its 2025 Annual Meeting of Stockholders (the 2025 Annual Meeting) on May 29, 2025. The following is a brief description of each matter voted upon at the 2025 Annual Meeting and the number of vote...

08 May 2025 8-K: Results of Operations and Financial Condition

- BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -

27 Mar 2025 8-K: Results of Operations and Financial Condition

- Three INDs cleared by US FDA for TYRA’s proprietary precision small molecules -

29 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 Nov 2024 8-K: Results of Operations and Financial Condition

- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support